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Background:  Women with angina and no obstructive coronary artery disease (CAD) often have ischemia and coronary microvascular 
dysfunction (CMD), yet evidence is lacking linking ischemia and angina in these women. To test the hypothesis that angina is due to 
ischemia in this population, we evaluated change in angina and cardiac magnetic resonance imaging (CMRI) myocardial perfusion over 
one year.
methods:  134 women with signs and symptoms of ischemia but no obstructive CAD underwent stress CMRI at baseline and one year 
using the same stress agent (adenosine or regadenoson). All were treated with optimized medical care; none had interval revascularization. 
CAAS MRV software (Pie Medical Imaging) was used to measure myocardial perfusion reserve index (MPRI), ventricular size and function. 
Medications and Seattle Angina Questionnaires (SAQ) were recorded. Signed rank test, McNemar’s exact test and Pearson correlation 
were performed.
results:  At baseline women had mean age 54 ± 11 yrs, body mass index 30 ± 8, Caucasian (68%), smoking history (43%), hypertension 
(35%), dyslipidemia (17%), and diabetes (10%). Angina and MPRI both improved at one year (Table), although correlations between SAQ, 
MPRI, and angina medications were not significant.
Conclusion:  Among women with signs and symptoms of ischemia and no obstructive CAD, angina and MPRI both improved at one-year 
follow-up. These observational results suggest that angina is due to ischemia and support conducting anti-ischemia trials in this population.
Cardiac Magnetic Resonance Imaging Parameters, Medication Use, and Angina
Variables (mean ± SD or %) Baseline 1 YearFollow-up P value
Myocardial Perfusion Reserve Index 1.76 ± 0.46 1.99 ± 0.55 0.0045
Peak Heart Rate During Stress (beats per minute) 95 ± 17 96 ± 15 0.25
Rate Pressure Product (bpm*mmHg) 12637 ± 3097 12527 ± 2764 0.66
Left Ventricular (LV) Mass (g) 94 ± 17 93 ± 18 0.18
LV end-diastolic volume (EDV) (mL) 121 ± 26 121 ± 23 0.51
Mass-to-volume ratio (LV mass/LV EDV) (g/mL) 0.80 ± 0.18 0.78 ± 0.20 0.07
LV Ejection Fraction (%) 68 ± 13 68 ± 6 0.77
Medications 
ACE Inhibitor
Angiotensin Receptor Blocker
Beta Blocker
Calcium Channel Blocker
Diuretic
Statin
Nitrate
Ranolazine
Selective Estrogen Modulator
.
19.8
6.4
33.6
13.5
14.2
46.9
29.7
5.6
6.9
.
24.4
7.4
41.5
17.1
11.3
55.7
26.6
17.7
2.4
.
0.38
0.74
0.19
0.44
0.32
0.13
0.28
0.0016
0.034
Seattle Angina Questionnaire
Physical Limitation Scale
Angina Stability Scale
Angina Frequency Scale
Treatment Satisfaction Scale
Disease Perception Scale
Average of 5 Scales
.
68 ± 25
48 ± 26
64 ± 26
71 ± 24
50 ± 24
60 ± 17
.
71 ± 25
53 ± 22
74 ± 24
79 ± 19
66 ± 24
68 ± 16
.
0.021
0.90
<0.0001
0.026
<0.0001
<0.0001
